Federal Register / Vol. 86, No. 162 / Wednesday, August 25, 2021 / Notices 47521 

information in support of the claim to 

Laura Bryant, Gilcrease Museum, 1400 

N Gilcrease Museum Road, Tulsa, OK 

74127, telephone (918) 596–2747, email 

laura-bryant@utulsa.edu, by September 

24, 2021. After that date, if no 

additional claimants have come 

forward, transfer of control of the sacred 

objects and/or objects of cultural 

patrimony to the Minnesota Chippewa 

Tribe, Minnesota (Mille Lacs Band) may 

proceed. 

The Gilcrease Museum is responsible 

for notifying the Minnesota Chippewa 

Tribe, Minnesota (Mille Lacs Band) that 

this notice has been published. 

Dated: August 11, 2021. 

Melanie O’Brien, 

Manager, National NAGPRA Program. 

[FR Doc. 2021–18270 Filed 8–24–21; 8:45 am] 

BILLING CODE 4312–52–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation No. 337–TA–1167] 

Certain Laparoscopic Surgical 

Staplers, Reload Cartridges, and 

Components Thereof; Commission 

Determination To Review in Part a 

Final Initial Determination Finding a 

Violation of Section 337; Schedule for 

Filing Written Submissions on the 

Issues Under Review and on Remedy, 

Public Interest, and Bonding 

AGENCY: U.S. International Trade 

Commission. 

ACTION: Correction of notice. 

SUMMARY: Correction is made to notice 

86 FR 46882, which was published on 

August 20, 2021. There is a 

typographical error in the investigation 

number on the first page caption 

section. The correct investigation 

number should read: Investigation No. 

337–TA–1167. 

By order of the Commission. 

Issued: August 20, 2021. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2021–18313 Filed 8–24–21; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—Dynamic Spectrum 

Alliance, Inc. 

Notice is hereby given that, on August 

10, 2021, pursuant to Section 6(a) of the 

National Cooperative Research and 

Production Act of 1993, 15 U.S.C. 4301 

et seq. (‘‘the Act’’), Dynamic Spectrum 

Alliance, Inc. has filed written 

notifications simultaneously with the 

Attorney General and the Federal Trade 

Commission disclosing changes in its 

membership. The notifications were 

filed for the purpose of extending the 

Act’s provisions limiting the recovery of 

antitrust plaintiffs to actual damages 

under specified circumstances. 

Specifically, Apple, Cupertino, CA, and 

Strathmore University, Nairobi, KENYA 

have been added as parties to this 

venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project. 

Membership in this group research 

project remains open, and Dynamic 

Spectrum Alliance, Inc. intends to file 

additional written notifications 

disclosing all changes in membership. 

On September 1, 2020, Dynamic 

Spectrum Alliance, Inc. filed its original 

notification pursuant to Section 6(a) of 

the Act. The Department of Justice 

published a notice in the Federal 

Register pursuant to Section 6(b) of the 

Act on September 18, 2020 (85 FR 

58390). 

The last notification was filed with 

the Department on May 4, 2021. A 

notice was published in the Federal 

Register pursuant to Section 6(b) of the 

Act on May 25, 2021 (86 FR 28150). 

Suzanne Morris, 

Chief, Premerger and Division Statistics, 

Antitrust Division. 

[FR Doc. 2021–18264 Filed 8–24–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–872] 

Bulk Manufacturer of Controlled 

Substances Application: Benuvia 

Therapeutics Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Benuvia Therapeutics Inc., 

has applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

SUPPLEMENTARY INFORMATION listed 

below for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before October 25, 2021. Such 

persons may also file a written request 

for a hearing on the application on or 

before October 25, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on July 1, 2021, Benuvia 

Therapeutics Inc., 2700 Oakmont Drive, 

Round Rock, Texas 78665, applied to be 

registered as a bulk manufacturer of the 

following basic class(es) of controlled 

substance(s): 

Controlled substance Drug 

code Schedule 

Marihuana ................................. 7360 I 

Tetrahydrocannabinols ............. 7370 I 

The company plans to bulk 

manufacture the listed controlled 

substances for the internal use 

intermediates or for sale to its 

customers. The company plans to 

manufacture the above-listed controlled 

substances in bulk to produce finished 

dosage forms and conduct research to 

develop new drug products and for 

clinical studies. In reference to drug 

codes 7360 (Marihuana), and 7370 

(Tetrahydrocannabinols), the company 

plans to bulk manufacture these drugs 

as synthetic. No other activities for these 

drug codes are authorized for this 

registration. 

Brian S. Besser, 

Acting Assistant Administrator. 

[FR Doc. 2021–18234 Filed 8–24–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–864] 

Importer of Controlled Substances 

Application: Cedarburg 

Pharmaceuticals 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Cedarburg Pharmaceuticals 

has applied to be registered as an 

importer of basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 


khammond on DSKJM1Z7X2PROD with NOTICES
47522 Federal Register / Vol. 86, No. 162 / Wednesday, August 25, 2021 / Notices 

comments on or objections to the 

issuance of the proposed registration on 

or before September 24, 2021. Such 

persons may also file a written request 

for a hearing on the application on or 

before September 24, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for a 

hearing should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on January 20, 2021, 

Cedarburg Pharmaceuticals, 870 Badger 

Circle Drive, Grafton, Wisconsin 53024– 

9436, applied to be registered as an 

importer of the following basic class(es) 

of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Gamma Hydroxybutyric Acid .... 2010 I 

Marihuana Extract ..................... 7350 I 

Marihuana ................................. 7360 I 

The company plans to import Sodium 

Oxybate (derivative of GammaHydroxybutyric Acid) to support 

Euticals Inc. post procurement quota 

grand. The cannabidiol from Marihuana 

and Marihuana Extracts is intended for 

analytical purposes with 

tetramethylpyrazine. No other activity 

for this drug code is authorized for this 

registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Brian S. Besser, 

Acting Assistant Administrator. 

[FR Doc. 2021–18233 Filed 8–24–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–890] 

Importer of Controlled Substances 

Application: Johnson Matthey Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Johnson Matthey Inc., has 

applied to be registered as an importer 

of basic class(es) of controlled 

substance(s). Refer to Supplementary 

Information listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before September 24, 2021. Such 

persons may also file a written request 

for a hearing on the application on or 

before September 24, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing must 

be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for a 

hearing should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on July 23, 2021, Johnson 

Matthey Inc., 2003 Nolte Drive, West 

Deptford, New Jersey 08066–1742, 

applied to be registered as an importer 

of the following basic class(es) of 

controlled substance(s): 

Controlled substance Drug 

code Schedule 

Nabilone .......................... 7379 II 

The company plans to import 

Nabilone (7379) in order to accept the 

return of this controlled substance from 

a foreign customer who no longer has a 

demand for this substance. No other 

activity for this drug code is authorized 

for this registration. 

Brian S. Besser, 

Acting Assistant Administrator. 

[FR Doc. 2021–18238 Filed 8–24–21; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–860] 

Bulk Manufacturer of Controlled 

Substances Application: Absolute 

Standards, Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Absolute Standards, Inc., has 

applied to be registered as a bulk 

manufacturer of basic class(es) of 

controlled substance(s). Refer to 

Supplementary Information listed below 

for further drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before October 25, 2021. Such 

persons may also file a written request 

for a hearing on the application on or 

before October 25, 2021. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on May 31, 2021, Absolute 

Standards, Inc., 44 Rossotto Drive, 

Hamden, Connecticut 06514–1335, 

applied to be registered as a bulk 

manufacturer of the following basic 

class(es) of controlled substance: 

Controlled substance Drug 

code Schedule 

Pentobarbital ................... 2270 II 

The company plans to bulk 

manufacture the listed controlled 

substances for internal use and for sale 

to its customers. No other activities for 

these drug codes are authorized for this 

registration. 

Brian S. Besser, 

Acting Assistant Administrator. 

[FR Doc. 2021–18230 Filed 8–24–21; 8:45 am] 

BILLING CODE P 


khammond on DSKJM1Z7X2PROD with NOTICES

I I 

I I 

I I